Kazia Therapeutics hosts virtual event on NDL2 cancer therapy
KZIA•Kazia Therapeutics will host a virtual event on Dec. 2, 2026, at 4 p.m. ET to discuss NDL2, a nuclear PD-L1 protein degrader initially targeting metastatic breast cancer and colorectal cancer.
1. Event details
Kazia Therapeutics will host a virtual event on Dec. 2, 2026, at 4 p.m. ET. Management will review NDL2’s development, with initial targets of metastatic breast cancer and colorectal cancer.
